Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The effects of preventive interventions on cardiovascular autonomic neuropathy (CAN) remain unclear. We examined the effect of intensively treating traditional risk factors for CAN, including hyperglycemia, hypertension, and dyslipidemia, in individuals with type 2 diabetes (T2D) and high cardiovascular risk participating in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. RESEARCH DESIGN AND METHODS: CAN was defined as heart rate variability indices below the fifth percentile of the normal distribution. Of 10,251 ACCORD participants, 71% (n = 7,275) had a CAN evaluation at study entry and at least once after randomization. The effects of intensive interventions on CAN were analyzed among these subjects through generalized linear mixed models. RESULTS: As compared with standard intervention, intensive glucose treatment reduced CAN risk by 16% (odds ratio [OR] 0.84, 95% CI 0.75–0.94, P = 0.003)—an effect driven by individuals without cardiovascular disease (CVD) at baseline (OR 0.73, 95% CI 0.63–0.85, P < 0.0001) rather than those with CVD (OR 1.10, 95% CI 0.91–1.34, P = 0.34) (Pinteraction = 0.001). Intensive blood pressure (BP) intervention decreased CAN risk by 25% (OR 0.75, 95% CI 0.63–0.89, P = 0.001), especially in patients ≥65 years old (OR 0.66, 95% CI 0.49–0.88, P = 0.005) (Pinteraction = 0.05). Fenofibrate did not have a significant effect on CAN (OR 0.91, 95% CI 0.78–1.07, P = 0.26). CONCLUSIONS: These data confirm a beneficial effect of intensive glycemic therapy and demonstrate, for the first time, a similar benefit of intensive BP control on CAN in T2D. A negative CVD history identifies T2D patients who especially benefit from intensive glycemic control for CAN prevention.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“High frequency (eg,10 kHz) spinal cord stimulation is a nonpharmacological approach that may be effective in persons with painful DPN that failed at least one medication, as suggested by a recent large RCT, leading to FDA approval in 2021 (Fig. 4).606,607”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [607]
Citations
Cites
Heart Rate Variability: Standards of Measurement, Physiological Interpretation, and Clinical Use
Electrophysiology, T. F. O. T. E. S. O. C. T. N. A. (1996) · Circulation · doi:10.1161/01.cir.93.5.1043 · Cited by 17,159
Heart rate variability: Standards of measurement, physiological interpretation, and clinical use
Malik, M., Bigger, J. T., Camm, A. J., Kleiger, R. E., Malliani, A., Moss, A. J., & Schwartz, P. J. (1996) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a014868 · Cited by 15,289
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“CAN persisted after transition to the standard glycemic control targets, which suggests a “metabolic memory” phenomenon such as that demonstrated in prior cohorts and for other diabetes complications (7,18).”
BackgroundGlucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378 · cited 1×
“(Intensified Multifactorial Intervention in Patients With Type 2 Diabetes and Microalbuminuria) trial demonstrated a 63% reduction in the rate of progression to CAN in individuals with type 2 diabetes (T2D) via intensive multifactorial interventions targetinghyperglycemia, hypertension, dyslipidemia, and lifestyle (10…”
BackgroundTesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690
Diabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602 · cited 9×
“For this analysis, we defined CAN as present (1) or absent (0) at each timepoint during”
BackgroundMethodInfluentialSelf-citationSilverman, M. G., Ference, B. A., Im, K., Wiviott, S. D., Giugliano, R. P., Grundy, S. M., Braunwald, E., & Sabatine, M. S. (2016) · JAMA · doi:10.1001/jama.2016.13985 · Cited by 1,483
Xie, X., Atkins, E., Lv, J., Bennett, A., Neal, B., Ninomiya, T., Woodward, M., MacMahon, S., Turnbull, F., Hillis, G. S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00805-3 · Cited by 980
Lv, J., Neal, B., Ehteshami, P., Ninomiya, T., Woodward, M., Rodgers, A., Wang, H., MacMahon, S., Turnbull, F., Hillis, G., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001293 · Cited by 777
Dabelea, D., Stafford, J. M., Mayer-Davis, E. J., D’Agostino, R., Dolan, L., Imperatore, G., Linder, B., Lawrence, J. M., Marcovina, S. M., Mottl, A. K., et al. (2017) · JAMA · doi:10.1001/jama.2017.0686 · Cited by 700
Self-citationAction to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods
Buse, J. B. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.003 · Cited by 661
Pop-Busui, R., Evans, G. W., Gerstein, H. C., Fonseca, V., Fleg, J. L., Hoogwerf, B. J., Genuth, S., Grimm, R. H., Corson, M. A., Prineas, R., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0125 · Cited by 540
Self-citationSchroeder, E. B., Liao, D., Chambless, L. E., Prineas, R. J., Evans, G. W., & Heiss, G. (2003) · Hypertension · doi:10.1161/01.hyp.0000100444.71069.73 · Cited by 452
Spallone, V. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0259 · Cited by 295
Braffett, B. H., Gubitosi-Klug, R. A., Albers, J. W., Feldman, E. L., Martin, C. L., White, N. H., Orchard, T. J., Lopes-Virella, M., Lachin, J. M., Pop-Busui, R., et al. (2020) · Diabetes · doi:10.2337/db19-1046 · Cited by 221 · cited 1×
“93) among patients with type 1 diabetes (19) that continues over time (20), but are at variance with thoseof theVeteransAffairsDiabetes Trial (VADT), in which intensive glycemic control did not show any beneficial effect on autonomic neuropathy among T2D subjects.”
BackgroundSelf-citationCarnethon, M. R., Prineas, R. J., Temprosa, M., Zhang, Z.-M., Uwaifo, G., Molitch, M. E., & for the Diabetes Prevention Program Research Group (2006) · Diabetes Care · doi:10.2337/diacare.29.04.06.dc05-1729 · Cited by 220
Ziegler, D., Zentai, C. P., Perz, S., Rathmann, W., Haastert, B., Döring, A., Meisinger, C., & for the KORA Study Group (2008) · Diabetes Care · doi:10.2337/dc07-1615 · Cited by 210
for the KORA Study Group, Ziegler, D., Voss, A., Rathmann, W., Strom, A., Perz, S., Roden, M., Peters, A., & Meisinger, C. (2015) · Diabetologia · doi:10.1007/s00125-015-3534-7 · Cited by 141
for the DCCT/EDIC Research Group, Pop-Busui, R., Herman, W. H., Feldman, E. L., Low, P. A., Martin, C. L., Cleary, P. A., Waberski, B. H., Lachin, J. M., & Albers, J. W. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0120-8 · Cited by 130
Self-citationFleg, J. L., Evans, G. W., Margolis, K. L., Barzilay, J., Basile, J. N., Bigger, J. T., Cutler, J. A., Grimm, R., Pedley, C., Peterson, K., et al. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07474 · Cited by 128
Self-citationPop-Busui, R., Braffett, B. H., Zinman, B., Martin, C., White, N. H., Herman, W. H., Genuth, S., Gubitosi-Klug, R., & the DCCT/EDIC Research Group (2017) · Diabetes Care · doi:10.2337/dc16-1397 · Cited by 116
Self-citationAndersen, S. T., Witte, D. R., Fleischer, J., Andersen, H., Lauritzen, T., Jørgensen, M. E., Jensen, T. S., Pop-Busui, R., & Charles, M. (2018) · Diabetes Care · doi:10.2337/dc18-1411 · Cited by 99 · cited 13×
“A negative CVD history identifies T2D patients who especially benefit from intensive glycemic control for CAN prevention.”
BackgroundInfluentialSelf-citationLaitinen, T. P., Lindström, J., Eriksson, J. G., Ilanne‐Parikka, P., Aunola, S., Keinanen-Kiukaanniemi, S. M., Tuomilehto, J. O., & Uusitupa, M. I. J. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03278.x · Cited by 94
Jaiswal, M., Divers, J., Urbina, E. M., Dabelea, D., Bell, R. A., Pettitt, D. J., Imperatore, G., Pihoker, C., Dolan, L. M., Liese, A. D., et al. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12633 · Cited by 90
Self-citationO'Neal, W. T., Chen, L. Y., Nazarian, S., & Soliman, E. Z. (2016) · Journal of Electrocardiology · doi:10.1016/j.jelectrocard.2016.06.008 · Cited by 69
Salman, I. M. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0625-x · Cited by 66 · cited 1×
“These findings were consistent with data showing that longterm BP control can reset baroreflex sensitivity (24), thereby preventing autonomic”
ResultGriffin, S. J., Rutten, G. E. H. M., Khunti, K., Witte, D. R., Lauritzen, T., Sharp, S. J., Dalsgaard, E.-M., Davies, M. J., Irving, G. J., Vos, R. C., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30349-3 · Cited by 55
Othman, A., Benghozi, R., Alecu, I., Yu, W., Niesor, E. J., von Eckardstein, A., & Hornemann, T. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.03.011 · Cited by 43
Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia
Melenovský, V., Wichterle, D., Šimek, J., Malík, J., Haas, T., Češka, R., & Malik, M. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00643-x · Cited by 27
Nestel, P. J., Khan, A. A., Straznicky, N. E., Mellett, N. A., Jayawardana, K. S., Mundra, P. A., Lambert, G. W., & Meikle, P. J. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.11.032 · Cited by 16
del Campo, L., Blanco‐Rivero, J., & Balfagón, G. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.03.056 · Cited by 12
Guan, J., Zhao, M., He, C., Li, X., Li, Y., Sun, J. L., Wang, W., Cui, Y., Zhang, Q., Li, B., et al. (2018) · Neuroscience Bulletin · doi:10.1007/s12264-018-0271-1 · Cited by 12
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citation12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gibbons, C. H., Giurini, J. M., Hilliard, M. E., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s012 · Cited by 207
12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., Callaghan, B. C., ChallaSivaKanaka, S., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s012 · Cited by 210
12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Callaghan, B. C., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s012 · Cited by 176
12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gibbons, C. H., Giurini, J. M., Hilliard, M. E., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s012 · Cited by 169
Metadata
- Authors
- Tang, Y., Shah, H., Bueno Junior, C. R., Sun, X., Mitri, J., Sambataro, M., Sambado, L., Gerstein, H. C., Fonseca, V., Doria, A., & Pop-Busui, R.
- Affiliations
- Joslin Diabetes Center (US)
- Research Division, Joslin Diabetes Center, Boston, MA
- Ca' Foncello Hospital (IT)
- Population Health Research Institute (CA)
- Tulane University (US)
- Division of Metabolism, Endocrinology & Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
- Corresponding author
- Doria, Alessandro
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-11-03
- Volume
- 44
- Issue
- 1
- Pages
- 164-173
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC7783932
- OpenAlex
- W3095717227
- Cited by
- 60
- References
- 35
- Citations by year
- 2026: 4 · 2025: 15 · 2024: 11 · 2023: 10 · 2022: 14 · 2021: 6
- FWCI
- 4.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Iacocca Foundation (Mary K. Iacocca Fellowship)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK107956-01, U01 DK119083)
- JDRF (DK36836)
- National Heart, Lung, and Blood Institute (N01-HC-95178, N01-HC-95179, N01-HC-95180, N01-HC-95181, N01-HC-95182, N01-HC-95183, N01-HC-95184, IAA-Y1-HC-9035, IAA-Y1-HC-1010)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- cardiac autonomic neuropathy, type 2 diabetes, tight glycemic control, intensive blood pressure control, fenofibrate, heart rate variability, ACCORD trial, cardiovascular risk, hypertension, dyslipidemia, older adults
- MeSH terms
- Aged, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Fenofibrate, Risk Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.